2021 China BioMed Innovation and Investment Conference Roadshow Application System is Online

2021-06-17 15:39

Established and initiated by China Pharmaceutical Innovation and Research Development Association (PhIRDA), the 2021 China BioMed Innovation and Investment Conference (2021 CBIIC) will be held on September 25-27 in Suzhou Industrial Park. With a history of previous 5 successful sessions, the CBIIC has become an annual dialogue between pharmaceutical innovation and investment globally, strongly supported by China’s government officials from National Medical Product Administration (NMPA), National Healthcare Security Administration (NHSA) and health authorities, and international leading financial and academic institutions including J.P. Morgan, Springer Nature, NEJM etc as well.

By the end of 2020, the CBIIC has been attended by 12000 participants and 4900 domestic and foreign pharmaceutical enterprises and investment institutions, with 500 innovative projects at home and abroad made roadshows. The CBIIC One-on-One Partnering System received over 15000 meeting requests and completed 1600 business negotiations, well praised by the industry and investment community. During the 2020 CBIIC, China's three pillar stock exchanges - Hong Kong Stock Exchange, Shanghai Stock Exchange and Shenzhen Stock Exchange - gathered in this event to present the significance of reform and development of China's capital market on the innovative pharmaceutical industry and jointly underpin the future of innovative healthcare industry. Under the background of the COVID-19 Era, the CBIIC committee newly established a series sessions including ChiNext Forum, Biomedical Innovation Cities Development Forum, Access to New Drug Policy Sharing Forum, and Virtual International Roadshow-Canada/Netherlands, to provide more valuable services for domestic and foreign participants, which were well-accepted and highly-recognized.

The 2021 CBIIC will continue to focus on "innovation" and "investment", providing high-quality roadshow projects, professional investors, and One-on-One Partnering System services for participants from an insider’s view and a strategic perspective. The 2021 CBIIC will bring you highlighting important topic from new investment trend and industry policy, experience sharing, global capital market listing related financial and legal advisory services, latest outcomes of pharmaceutical R&D, research reports and so on.

2021 CBIIC will include about 15 parallel sessions: Clinical Trial Data Release, Roadshows for Listed and Non-Listed Companies, Medical Devices, International Projects, R&D/Service Agencies (CRO, CMO, CDMO),WIT-MED + Big Data, Rare Diseases and Orphan Drugs, Artificial Intelligence (AI) + BioMed, and Forums for Investors’ Experience Sharing, SSE STAR Market, ChiNext, Financing M&A, Access to New Drug Policy Sharing, meeting diversified needs of participants.


2021 CBIIC Roadshow Application System is Officially Online Today !

Places in the roadshow projects are limited, please apply now to avoid disappointment.

CBIIC Website:  http://cbiic.phirda.com/?lang=en-us

Please visit CBIIC Website on PC to apply for roadshow.

Deadline of Roadshow Application: July 20, 2021


Contact: Yang Yuanlin

Tel: +86 010-58156093-816

Cell: +86 18511990895

mail: yangyl@phirda.com


Highlights of 2021 CBIIC

l  Live Broadcast of Opening Ceremony

l  Clinical Trial Data Release of Innovative Drugs

l  Domestic and Foreign KOLs

l  Focus on Latest Hot Topics

l  Face to Face Conversation with Investors

l  One-on-One Partnering System

l  Excellent Parallel Sessions

l  Authoritative Domestic and Foreign Media Report

l  English-Chinese Simultaneous Interpretation